======= EGR2 =======
== Gene Information ==
* **Official Symbol**: EGR2
* **Official Name**: early growth response 2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=1959|1959]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P11161|P11161]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=EGR2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20EGR2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/129010|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: The protein encoded by this gene is a transcription factor with three tandem C2H2-type zinc fingers. Defects in this gene are associated with Charcot-Marie-Tooth disease type 1D (CMT1D), Charcot-Marie-Tooth disease type 4E (CMT4E), and with Dejerine-Sottas syndrome (DSS). Multiple transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Oct 2008].
* **UniProt Summary**: Sequence-specific DNA-binding transcription factor. Binds to two specific DNA sites located in the promoter region of HOXA4. {ECO:0000269|PubMed:21836637}.
|zf-C2H2|
|DUF3446|
|rhombomere 5 morphogenesis|
|rhombomere 3 formation|
|rhombomere 5 formation|
|rhombomere formation|
|rhombomere 3 morphogenesis|
|rhombomere morphogenesis|
|rhombomere 3 development|
|central nervous system segmentation|
|brain segmentation|
|rhombomere 5 development|
|rhombomere development|
|SUMO ligase activity|
|facial nerve structural organization|
|facial nerve morphogenesis|
|facial nerve development|
|cranial nerve structural organization|
|HMG box domain binding|
|anatomical structure arrangement|
|preganglionic parasympathetic fiber development|
|parasympathetic nervous system development|
|rhythmic behavior|
|motor neuron axon guidance|
|cranial nerve morphogenesis|
|Schwann cell differentiation|
|autonomic nervous system development|
|skeletal muscle cell differentiation|
|cranial nerve development|
|regulation of neuronal synaptic plasticity|
|RNA polymerase II activating transcription factor binding|
|protein sumoylation|
|peripheral nervous system development|
|nerve development|
|segmentation|
|fat cell differentiation|
|myelination|
|axon ensheathment|
|ensheathment of neurons|
|skeletal muscle tissue development|
|skeletal muscle organ development|
|protein export from nucleus|
|hindbrain development|
|nuclear export|
|glial cell differentiation|
|regulation of synaptic plasticity|
|regulation of ossification|
|gliogenesis|
|transcription regulatory region DNA binding|
|response to insulin|
|learning or memory|
|axon guidance|
|neuron projection guidance|
|nucleocytoplasmic transport|
|nuclear transport|
|rhythmic process|
|striated muscle tissue development|
|ubiquitin protein ligase binding|
|muscle organ development|
|muscle tissue development|
|cognition|
|peptidyl-lysine modification|
|regionalization|
|axonogenesis|
|response to peptide hormone|
|chromatin binding|
|axon development|
|cell morphogenesis involved in neuron differentiation|
|pattern specification process|
|modulation of chemical synaptic transmission|
|regulation of trans-synaptic signaling|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|response to peptide|
|muscle structure development|
|neuron projection morphogenesis|
|transcription by RNA polymerase II|
|plasma membrane bounded cell projection morphogenesis|
|cell projection morphogenesis|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|cell part morphogenesis|
|chemotaxis|
|taxis|
|cell morphogenesis involved in differentiation|
|behavior|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|neuron projection development|
|DNA-binding transcription factor activity|
|intracellular membrane-bounded organelle|
|cell morphogenesis|
|brain development|
|protein modification by small protein conjugation|
|head development|
|neuron development|
|cellular component morphogenesis|
|peptidyl-amino acid modification|
|anatomical structure formation involved in morphogenesis|
|response to hormone|
|central nervous system development|
|protein modification by small protein conjugation or removal|
|intracellular protein transport|
|response to organonitrogen compound|
|neuron differentiation|
|response to nitrogen compound|
|nucleobase-containing compound biosynthetic process|
|plasma membrane bounded cell projection organization|
|cell projection organization|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|positive regulation of transcription by RNA polymerase II|
|organic cyclic compound biosynthetic process|
|locomotion|
|nervous system process|
|response to endogenous stimulus|
|protein transport|
|intracellular transport|
|generation of neurons|
|peptide transport|
|positive regulation of transcription, DNA-templated|
|movement of cell or subcellular component|
|response to oxygen-containing compound|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|amide transport|
|cellular protein localization|
|cellular macromolecule localization|
|establishment of protein localization|
|neurogenesis|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|cell development|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|positive regulation of RNA metabolic process|
|tissue development|
|macromolecule biosynthetic process|
|establishment of localization in cell|
|nitrogen compound transport|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|system process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp4|Actinomycin-D 0.01μM R00 exp4]]|-2.55|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|-2.4|
|[[:results:exp96|BI-2536 0.02μM R03 exp96]]|-2.18|
|[[:results:exp508|NN-Dimethylsphingosine 2.5μM R08 exp508]]|-2.04|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-1.94|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|-1.92|
|[[:results:exp244|SB743921 0.001μM R05 exp244]]|-1.8|
|[[:results:exp26|Oligomycin-A 20μM R00 exp26]]|-1.78|
|[[:results:exp211|AICAR 240μM R05 exp211]]|-1.76|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-1.73|
|[[:results:exp126|GSK461364A 0.1μM R03 exp126]]|-1.72|
|[[:results:exp8|Brefeldin A 0.02μM R00 exp8]]|-1.71|
|[[:results:exp415|Trichostatin-A 0.06μM R07 exp415]]|1.7|
|[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|1.73|
|[[:results:exp352|Dexamethasone 0.006 to 0.015μM on day4 R07 exp352]]|1.76|
|[[:results:exp279|D-Fructose 10000μM R06 exp279]]|1.79|
|[[:results:exp486|Heregulin-B 44ng/ml R08 exp486]]|1.82|
|[[:results:exp16|DABN 2μM R00 exp16]]|1.85|
|[[:results:exp432|YM155 0.001μM R08 exp432]]|1.88|
|[[:results:exp61|YM155 0.0002μM R01 exp61]]|2.06|
|[[:results:exp71|KU-0063794 3.8μM R02 exp71]]|2.18|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|2.28|
|[[:results:exp10|CCCP 0.1μM R00 exp10]]|2.58|
|[[:results:exp18|Doxycycline 10μM R00 exp18]]|2.78|
^Gene^Correlation^
|[[:human genes:r:rrm1|RRM1]]|0.594|
|[[:human genes:c:c14orf93|C14orf93]]|0.503|
|[[:human genes:t:tfip11|TFIP11]]|0.496|
|[[:human genes:t:tbc1d3g|TBC1D3G]]|0.495|
|[[:human genes:t:tbc1d3h|TBC1D3H]]|0.494|
|[[:human genes:s:slc6a17|SLC6A17]]|0.481|
|[[:human genes:v:vasn|VASN]]|0.48|
|[[:human genes:t:tceb3cl2|TCEB3CL2]]|0.478|
|[[:human genes:n:nupl1|NUPL1]]|0.477|
|[[:human genes:t:tceb3c|TCEB3C]]|0.467|
|[[:human genes:p:psap|PSAP]]|0.467|
|[[:human genes:t:tbc1d3f|TBC1D3F]]|0.464|
|[[:human genes:r:rps2|RPS2]]|0.459|
|[[:human genes:e:eif4a3|EIF4A3]]|0.458|
|[[:human genes:t:tceb3cl|TCEB3CL]]|0.455|
|[[:human genes:c:ckap5|CKAP5]]|0.454|
|[[:human genes:o:orc6|ORC6]]|0.453|
|[[:human genes:p:psmb4|PSMB4]]|0.45|
|[[:human genes:s:smtn|SMTN]]|0.448|
|[[:human genes:c:cdc6|CDC6]]|0.445|
|[[:human genes:o:orc1|ORC1]]|0.44|
|[[:human genes:t:tpx2|TPX2]]|0.44|
|[[:human genes:f:fam231a|FAM231A]]|0.44|
|[[:human genes:f:fam231c|FAM231C]]|0.44|
|[[:human genes:t:tbc1d3|TBC1D3]]|0.437|
|[[:human genes:s:slc4a1|SLC4A1]]|0.432|
|[[:human genes:g:golga8o|GOLGA8O]]|0.431|
|[[:human genes:t:tp53tg3b|TP53TG3B]]|0.43|
|[[:human genes:t:tp53tg3|TP53TG3]]|0.429|
|[[:human genes:t:tp53tg3c|TP53TG3C]]|0.429|
|[[:human genes:c:cep192|CEP192]]|0.428|
|[[:human genes:p:psmb3|PSMB3]]|0.428|
|[[:human genes:p:polr2j3|POLR2J3]]|0.428|
|[[:human genes:i:iscu|ISCU]]|0.428|
|[[:human genes:s:supt5h|SUPT5H]]|0.427|
|[[:human genes:c:ccna2|CCNA2]]|0.424|
|[[:human genes:a:aamp|AAMP]]|0.423|
|[[:human genes:c:c1qtnf9b|C1QTNF9B]]|0.422|
|[[:human genes:s:s1pr4|S1PR4]]|0.421|
|[[:human genes:r:rrn3|RRN3]]|0.419|
|[[:human genes:e:exosc5|EXOSC5]]|0.418|
|[[:human genes:m:msh5|MSH5]]|0.418|
|[[:human genes:a:aprt|APRT]]|0.418|
|[[:human genes:g:gar1|GAR1]]|0.418|
|[[:human genes:t:tbc1d3c|TBC1D3C]]|0.416|
|[[:human genes:c:copg1|COPG1]]|0.416|
|[[:human genes:p:psmb2|PSMB2]]|0.415|
|[[:human genes:g:golga6l1|GOLGA6L1]]|0.415|
|[[:human genes:c:cdca3|CDCA3]]|0.412|
|[[:human genes:r:rbm39|RBM39]]|0.412|
|[[:human genes:k:kif3c|KIF3C]]|0.412|
|[[:human genes:m:med14|MED14]]|0.41|
|[[:human genes:d:dock6|DOCK6]]|0.409|
|[[:human genes:a:aqr|AQR]]|0.409|
|[[:human genes:g:gon4l|GON4L]]|0.408|
|[[:human genes:t:tuba8|TUBA8]]|0.408|
|[[:human genes:h:hist1h2be|HIST1H2BE]]|0.407|
|[[:human genes:p:psmd3|PSMD3]]|0.407|
|[[:human genes:c:chd4|CHD4]]|0.406|
|[[:human genes:r:rps12|RPS12]]|0.406|
|[[:human genes:c:cbwd3|CBWD3]]|0.405|
|[[:human genes:c:cactin|CACTIN]]|0.405|
|[[:human genes:t:tbc1d3l|TBC1D3L]]|0.405|
|[[:human genes:t:tbc1d3k|TBC1D3K]]|0.404|
|[[:human genes:t:tbc1d3e|TBC1D3E]]|0.404|
|[[:human genes:u:utp3|UTP3]]|0.404|
|[[:human genes:t:tbc1d3i|TBC1D3I]]|0.403|
|[[:human genes:i:ik|IK]]|0.403|
|[[:human genes:o:or10g3|OR10G3]]|0.402|
|[[:human genes:d:ddtl|DDTL]]|0.402|
|[[:human genes:r:rrp7a|RRP7A]]|0.401|
|[[:human genes:r:rbbp5|RBBP5]]|0.401|
|[[:human genes:c:chaf1a|CHAF1A]]|0.4|
|[[:human genes:a:add2|ADD2]]|0.4|
|[[:human genes:z:zfand5|ZFAND5]]|0.4|
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 1801
* **Expression level (log2 read counts)**: -0.84
{{:chemogenomics:nalm6 dist.png?nolink |}}